The 2012 review reports that low magnesium intakes and blood levels have been associated with hypertension, atherosclerotic vascular disease, and sudden cardiac death, and separately with elevated C-reactive protein. That is the whole of the cardiovascular evidence curated here. The 2016 trial describes magnesium in passing as a high-quality natural calcium antagonist in cardiology, but that is the authors’ framing of why they chose to study it, and the trial they ran measured heart rate variability, not blood pressure, vascular tone, or cardiovascular events. No curated source here is a trial of magnesium supplementation with a blood pressure or cardiovascular event endpoint, so this page claims an association with low magnesium status, not a demonstrated risk reduction from supplementing.
The curated review places type 2 diabetes and metabolic syndrome at the head of its list of conditions associated with low magnesium intakes and blood levels. It also notes that the prevalence and incidence of type 2 diabetes in the United States rose sharply between 1994 and 2001 as the calcium-to-magnesium intake ratio from food rose from below 3.0 to above 3.0 — a temporal co-occurrence the authors flag as worth investigating, not a demonstrated cause. Understanding how low magnesium status and rising calcium-to-magnesium ratios influence the incidence of type 2 diabetes and metabolic syndrome is one of the research priorities the review closes on.
What this page does not claim: no source curated here measured insulin sensitivity, fasting glucose, or HbA1c under magnesium supplementation, so the earlier claim that supplementation improves insulin sensitivity has been withdrawn rather than restated. Nor does either abstract establish that magnesium is a cofactor for insulin receptor signaling or that low magnesium impairs the ability of cells to respond to insulin; that mechanism has been removed along with the outcome claim it was there to explain.
The one interventional source curated here is a randomised, controlled, two-armed parallel study of 100 participants over 90 days, in which 400 mg of magnesium a day was given in combination with strength-endurance training. Heart rate variability improved in the magnesium group: pNN50, an indicator of parasympathetic activity, increased, while the LF-HF ratio and the stress index decreased. The control group showed no positive change in HRV parameters, and no effect on intracellular magnesium concentration could be shown. The authors conclude that people under mental and physical stress can benefit from a daily intake of magnesium.
Read that result at its own scope. The trial reports no numeric results, confidence intervals, or p-values in its abstract, describes no placebo or blinding, and was published as a German-language supplement article; HRV is a physiological marker of autonomic balance, not a symptom outcome.
What this page does not claim: the trial did not measure sleep onset, sleep quality, anxiety, mood, or cortisol. Its closing mention of restlessness, irritability, poor concentration, sleep disorder, and depression is a hypothesis about preventing deficiency, not a measured endpoint. This page therefore carries no sleep-quality claim, and will carry none until evidence that measured sleep is curated.
The curated review names osteoporosis among the conditions associated with low magnesium intakes and blood levels, and again among the inflammation-related disorders it flags for further research. That is the extent of the bone evidence here. The review reports no bone mineral density or fracture outcome, and no curated source measures a bone endpoint under supplementation, so the bone claim on this page stops at the osteoporosis association.
The only magnesium dose any source curated here administered is the one in the trial above: 400 mg a day for 90 days, given alongside strength-endurance training to participants under mental and physical stress, with no demonstrable effect on intracellular magnesium concentration. That is one trial’s protocol, not a recommended intake. The 2012 review speaks to requirement rather than dose, and does so with a caveat attached: it measures its shortfall figure against magnesium from food, warns that Dietary Reference Intakes determined by balance studies may themselves be misleading if the subjects assumed to be healthy carry chronic latent magnesium deficiency, and lists refining the magnesium requirement among its research priorities. Its only remark on supplements is that supplement intake, excluded from its calcium-to-magnesium food-intake ratios, tends to favor calcium over magnesium.
What this page does not claim: dosing, forms, food sources, or safety. None of the three curated references states an intake target, compares magnesium salts, measures absorption or gastrointestinal tolerability, reports the magnesium content of any food, or addresses how impaired kidneys handle magnesium. The RDA and supplemental-range figures, the magnesium oxide absorption and tolerability line, the dietary-source amounts, the kidney-disease caution, and the form-by-form guidance previously carried here — for glycinate, L-threonate, malate, and taurate, together with their sleep, cognitive, muscle, and cardiovascular rationales — have been removed rather than kept behind a disclaimer, since a disclaimer does not make an unsourced health claim publishable. Their absence is a sourcing gap, not a safety clearance: this page offers no guidance on how much magnesium to take, in which form, or with which medical conditions, and will offer none until evidence that establishes it is curated.
What this page does not claim: magnesium’s general physiology. Neither abstract states how abundant magnesium is in the body, how many enzymatic reactions it takes part in, what share of it is stored in bone, or how it acts on vascular smooth muscle, insulin receptors, osteoblasts, osteoclasts, parathyroid hormone, or vitamin D metabolism. The abundance ranking, the 300-plus-enzymes figure with its DNA, protein, nerve, and energy examples, the peripheral-resistance line, the insulin-signaling line, and the 60%-of-body-magnesium-in-bone line previously carried here have been removed rather than kept as background, since prose that predates an audit is not sourced by having been written first. The one mechanistic statement the review itself makes, it offers as an open question: that cellular magnesium deficit, perhaps involving TRPM6/7 channels, elicits calcium-activated inflammatory cascades independent of injury or pathogens.
What this page does not claim: magnesium and muscle function. Neither curated study measured muscle cramps, muscle performance, or exercise recovery. The HRV trial ran alongside strength-endurance training and described increased vagal activity as adaptive and regenerative capacity, but that is an interpretation of an autonomic marker, not a muscle outcome; the survey review does not mention muscle at all. The muscle claim previously carried here has been withdrawn, and the Examine overview — a general summary that could not be opened in its cited form — is not treated as claim-level support for it or anything else on this page.